Skip to content

A randomized, double-blind, placebo-controlled, multicenter, multicenter clinical study of synovitis granules in the treatment of knee osteoarthritis

A randomized, double-blind, placebo-controlled, multicenter, multicenter clinical study of synovitis granules in the treatment of knee osteoarthritis

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-17011954
Enrollment
Unknown
Registered
2017-07-12
Start date
2017-07-15
Completion date
Unknown
Last updated
2017-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis of the knee

Interventions

Sponsors

The Third Hospital of Hebei Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. according to the diagnostic criteria of knee osteoarthritis, clinical diagnosis of osteoarthritis of the knee; 2. Imaging findings of the knee indicate joint effusion and / or synovitis; 3. 40 years of age or older, male or female; 4. agree to participate in the clinical trial and sign the informed consent voluntarily.

Exclusion criteria

Exclusion criteria: 1. Kellgren-Lawrecne, knee osteoarthritis, X-ray classification, grade 4 patients; 2. osteoarthritis of the knee caused by rheumatoid arthritis, traumatic arthritis, gouty arthritis, tuberculosis, or allergies; 3. infection, fracture, dislocation, ligament rupture, meniscus injury, pigmented villonodular synovitis, hemophilia arthritis and so on, can cause joint pain, swelling and dysfunction of the disease; 4. combined with heart, liver, kidney, hematopoietic system and other important organs and systems, serious primary diseases, ALT, AST > 1.5 times the normal value, Cr > 133 mu mol/L; 5. joint pain degree evaluation of any VAS score more than 7 points; 6. have a history of drug abuse, alcohol abuse or mental illness; 7. pregnant women, lactating women and the recent fertility program; 8. allergic to the known components of this test drug and allergic constitution; 9. participated in other clinical trials in the first 3 months; 10. the researchers found it inappropriate to participate in the study.

Design outcomes

Primary

MeasureTime frame
Kellgren-Lawrence;womac;

Countries

China

Contacts

Public ContactBaicheng Chen

The Third Hospital of Hebei Medical University

377480696@qq.com+86 13810072342

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026